Abstract:Background Adverse pregnancy outcomes, which can be caused by multiple factors, present a significant threat to the health of mothers and their babies. Cell‐free fetal DNA (cffDNA) from placental trophoblast cells might be able to reflect placental and fetal status. Previous studies have yielded controversial results regarding the association of FF or cffDNA with various adverse pregnancy outcomes. A previous study has attempted to systematically assess the association between low fetal fraction (FF) and adverse pregnancy outcomes, but it failed to perform quantitative analyses due to the few studies included. In the present study, we attempted to quantitatively assess the association of FF (or cffDNA) with adverse pregnancy outcomes and further analyze the causes of heterogeneity. Objectives To investigate the association of high/low FF or cffDNA with adverse pregnancy outcomes. Search Strategy We searched the databases of PubMed, Embase, Cochrane, and Web of Science from January 1, 1990, to June 15, 2022 in this meta‐analysis. Selection Criteria Studies on the relationships of adverse pregnancy outcomes in women with FF or cell free DNA were included. Non‐English literature was excluded. Data Collection and Analysis Data about pregnancy outcomes and cell free DNA were extracted and meta‐analyzed. Subgroup analysis was performed by different outcomes. Main Results There were 11 studies included involving 8280 participants. No significant heterogeneity was observed among the studies (I2 = 27%, 25%), and a fixed‐effect model was used for weighted quantitative analysis. The results revealed that the FF or cffDNA during pregnancy was significantly associated with adverse pregnancy outcomes in pregnant women (OR = 1.57, 95% CI [1.24, 1.99], P = 0.233). The overall incidence of the maternal adverse outcomes was 8% (95% CI: 5–13). Subgroup analysis of different outcomes showed an evident association between low FF or cffDNA and hypertensive disorders of pregnancy (HDP) (OR = 1.76, 95% CI [1.36, 2.27], P = 0.581). There was no evidence that the occurrence of spontaneous preterm birth (sPTB) and placental abnormality was associated with FF or cffDNA. No association was observed between low FF or cffDNA during pregnancy and adverse outcomes in fetuses (OR = 1.39, 95% CI [0.99, 1.94], P = 0.242). The overall incidence of adverse outcomes in fetuses was 8% (95% CI: 6–11). There were controversies over the association between high FF or cffDNA and HDP, and sPTB and small for gestational age infant, among different studies. Conclusions Pregnant women with low FF or cffDNA during the first or second trimester of pregnancy have an overall increased risk of adverse pregnancy outcomes, especially HDP. However, the association between FF and various pregnancy outcomes needs to be further explored by more prospective studies.

Successive refinement on trees: a special case of a new MD coding region

PADGEM protein.

A method for noninvasive detection of fetal large deletions/duplications by low coverage massively parallel sequencing.

Effective Noninvasive Zygosity Determination By Maternal Plasma Target Region Sequencing

Noninvasive inferring expressed genes and in vivo monitoring of the physiology and pathology of pregnancy using cell-free DNA

Advances of the Adverse Effects of Paternal Factors on Fetal Development

Cell-free nucleic acids in (maternal) blood: any relevance to (reproductive) immunologists?

Non-invasive Prenatal Testing Reveals Copy Number Variations Related to Pregnancy Complications

Detection of fetal trisomy and single gene disease by massively parallel sequencing of extracellular vesicle DNA in maternal plasma: a proof-of-concept validation

Detectionof Fetal Trisomy 8 Mosaicism with Cell-free Fetal DNA in Maternal Plasma

Small Non-Coding RNAs Transfer Through Mammalian Placenta and Directly Regulate Fetal Gene Expression

Integrative single-cell and cell-free plasma RNA transcriptomics elucidates placental cellular dynamics

Transfer cells: cells specialized for a special purpose.

Isolation and Whole Genome Sequencing of fetal cells from maternal blood towards the ultimate non-invasive prenatal testing.

DNA Methylome Profiling of Maternal Peripheral Blood and Placentas Reveal Potential Fetal DNA Markers for Non-Invasive Prenatal Testing.

Cell-free DNA Methylation and Transcriptomic Signature Prediction of Pregnancies with Adverse Outcomes

High-resolution epigenomic liquid biopsy for noninvasive phenotyping in pregnancy

Size-tagged preferred ends in maternal plasma DNA shed light on the production mechanism and show utility in noninvasive prenatal testing

Association of fetal fraction and cell‐free fetal DNA with adverse pregnancy outcomes: A systematic review

Advanced Whole-Genome Sequencing and Analysis of Fetal Genomes from Amniotic Fluid.

Elevated Levels of Total Cell-Free DNA in Maternal Serum Samples Arise from the Generation of Neutrophil Extracellular Traps